BIOKIN PHARMACEUTICAL(SH:688506) Ge Long Hui A P P·2025-10-26 08:29Core Viewpoint - The company reported significant growth in revenue and net profit for Q3 2025, primarily driven by successful collaboration with BMS and milestone achievements in clinical trials [1] Financial Performance - The company's revenue for Q3 2025 reached RMB 1.895 billion, representing a year-on-year increase of 1,625.08% [1] - The net profit attributable to shareholders was RMB 623 million, while the net profit excluding non-recurring gains and losses was RMB 601 million [1] - Basic earnings per share stood at RMB 1.55 [1] Key Drivers of Growth - Revenue growth was mainly attributed to the successful advancement of the collaboration with BMS [1] - The achievement of a milestone in the global II/III phase key registration clinical trial IZABRIGHT-Breast01 on September 30, 2025, triggered the recognition of the first payment of USD 250 million under the collaboration agreement [1]